Medifast (MED) Q2 2026 earnings review
Top Line Stabilizes, But the Core Engine Continues to Erode
Medifast managed to halt its sequential revenue slide in Q2, posting $76.4 million to match Q1 levels. However, the mechanics beneath this stabilization are precarious. The company's core growth engine—independent active earning coaches—collapsed 48.7% YoY to just 11,700. The only factor preventing a total revenue freefall is an accelerating surge in coach productivity, with revenue per coach spiking 41% to $6,529. Management touted 'signs of a turnaround' and a new brand launch ('Trilivy'), but Q3 guidance of $70 million (midpoint) implies a reversing sequential trend. Reaching the promised Q4 profitability inflection will require flawless execution of the new Catalyst cost-savings program.
🐂 Bull Case
Average revenue per active coach hit $6,529, a staggering 41% YoY increase. The remaining coaches are highly engaged and structurally aligned, successfully extracting more value per client.
With nearly $170 million in cash and zero debt, Medifast has the financial durability to fund its Trilivy rebranding and Catalyst restructuring efforts without existential liquidity risks.
🐻 Bear Case
The active coach count has been halved in a single year (22,800 to 11,700). Productivity gains have a mathematical ceiling; without a stabilized coach base, revenue will inevitably resume its downward trajectory.
Gross margins are suffering from severe fixed-cost deleveraging, dropping to 69.9%. Q3 guidance points to lower sequential revenue, making the targeted Q4 return to profitability highly dependent on aggressive cost-cutting.
⚖️ Verdict: 🔴
Bearish. While sequential top-line stability is a positive milestone, the continued acceleration in coach attrition outweighs the productivity gains. The underlying business model remains heavily stressed by GLP-1 disruption.
Key Themes
The Bottomless Coach Collapse
The foundation of Medifast's business model is its coach network, which is experiencing a severely decelerating trend. Q2 active coaches plummeted 48.7% YoY to 11,700. More alarming is management's explicit admission in the release that they expect the number of active earning coaches 'to continue to decline in 2026.' This structural shrinkage places immense pressure on the remaining network to continuously increase output.
Unprecedented Coach Productivity
To offset the loss of half its workforce, the remaining coach base is operating at historic efficiency. Revenue per active earning coach accelerated for the third consecutive quarter, surging 41% YoY to $6,529. Management attributes this to prioritizing productive coaches and deploying more efficient network structures. This metric is the sole reason Q2 revenue remained sequentially stable.
Contradictory Guidance Undermines 'Stabilization' Narrative
Management's narrative heavily emphasized that 'revenue remained sequentially stable' ($76.0M in Q1 to $76.4M in Q2). However, Q3 guidance calls for $60M-$80M. The $70M midpoint implies an 8% sequential decline, reversing the hard-fought stabilization and signaling that the top-line bleed has not truly bottomed.
GLP-1 Disruption Dictates the Battlefield
The rapid consumer adoption of GLP-1 weight-loss medications remains the apex predator for Medifast's legacy business. Management explicitly cited this dynamic as the primary driver behind continued client acquisition pressure. The company's entire forward strategy is a defensive maneuver designed to coexist with, rather than fight, this pharmaceutical shift.
Trilivy Rebranding and the Metabolic Health Institute
Medifast is abandoning its legacy 'Optavia' weight-loss identity to launch 'Trilivy' alongside new 'Reset Fuelings.' This represents Medifast 3.0, pivoting purely to 'Metabolic Synchronization.' The success of these newly introduced tools will determine if the company can capture the 'GLP-1 off-ramp' market they have heavily targeted in recent quarters.
Catalyst Program Restructuring
With top-line growth elusive, management has launched the 'Catalyst' program to engineer profitability through cost containment. Early actions include renegotiating the Havre de Grace distribution facility lease (reducing square footage). The bulk of execution is slated for Q3, targeting facility rationalization and AI-related efficiencies to reverse operating losses.
Margin Deleveraging on Fixed Costs
Lower volumes are punishing margins. Gross margin decelerated from 72.6% a year ago to 69.9% in Q2. Similarly, SG&A dropped 25.7% in absolute dollars, but deleveraging caused it to increase by 200 basis points as a percentage of revenue (to 75.6%). Cost cuts are currently losing the race against revenue declines.
Other KPIs
Cash, cash equivalents, and investments slightly grew from $167.3M at the end of FY25. The company remains completely debt-free. This fortress balance sheet is critical, providing Medifast the necessary capital runway to absorb operating losses ($4.3M in Q2) while funding the Catalyst restructuring and Trilivy brand launch.
SG&A expenses fell 25.7% YoY, driven primarily by a $12.6M drop in coach compensation (tied to lower volume), a $2.3M drop in salaries, and a $2.0M cut to company-led marketing. While absolute costs are down, fixed-cost deleverage remains a structural headwind until revenue growth resumes.
Guidance
Reversing. The $70 million midpoint implies a 21.7% YoY decline (compared to $89.4M in Q3 2025) and an 8.4% sequential decline from Q2 2026. This breaks the sequential stability achieved in Q1 and Q2.
Stable. The $0.40 loss midpoint indicates profitability remains elusive in the near term as the company incurs execution costs for the Catalyst program. Return to profitability is not modeled until Q4.
Stable. Management maintained its full-year guide. The $285M midpoint implies a roughly 26% YoY decline from FY 2025 revenue ($385.8M). Achieving the midpoint requires approximately $132.5M in H2 2026 revenue, which aligns with Q3 guidance.
Stable. The wide range reflects the variability in expected Catalyst restructuring savings and Trilivy adoption. Reaching the optimistic end of this range (-$0.25) implies a significant margin inflection in Q4.
Key Questions
Revenue per Coach Ceiling
Revenue per coach surged 41% to over $6,500. Is there a natural ceiling to how many clients a single coach can manage effectively, and are we approaching that limit?
Guidance Disconnect
Management highlighted sequential revenue stability as a leading indicator of a turnaround, yet Q3 guidance implies a sequential decline. What specific dynamics are driving the anticipated step-down in Q3?
Catalyst Program Economics
Can management quantify the expected run-rate savings from the newly launched Catalyst program, specifically separating facility rationalization from AI-related efficiencies?
Trilivy Adoption Metrics
With the launch of Trilivy and Reset Fuelings, what early conversion rates are you seeing among current clients, and is it successfully attracting the targeted GLP-1 'off-ramp' demographic?